Trading at $124.50, Dexcom’s stock is riding a steady uptrend channel since early March, supported by consistent upward revisions to revenue estimates within the medtech space. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. DexCom raised its outlook for 2025 revenues. The company now expects revenues to be in the range of $4.6-$4.625 billion (previously $4.6 billion), implying 14-15% year-over-year growth. The Zacks Consensus Estimate was pegged at $4.61 billion. With Dexcom stock price at $121.75, some traders are watching RSI levels peaking near 68, hinting at possible short-term consolidation before another upward leg driven by medical device demand.